Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: A systematic review and meta-analysis

Nicola Veronese, Laura D. Wood, Alcides Chaux, Enzo Manzato, Hanbyoul Cho, Jae-Hoon Kim, Angela Chou, Duck-Woo Kim, George J. Netto, Xianyu Zhang, Nicola Veronese, Sheila F. Faraj, Satoru Kyo, Claudio Luchini, Hai-Bo Yan, David F. Schaeffer, Soo Young Lee, Aldo Scarpa, Feng Liu, Kentaro NakayamaFeng Liu, Aldo Scarpa, Zsuzsanna Lichner, Marco Solmi, Steve E. Kalloger, Paola Capelli, Martin Köbel, Christoph U. Correll, Giuseppe Sergi, George M. Yousef, Andreas Scorilas, Da Pang, Gregg S. Nelson, Yoshihito Yokoyama, Anthony J. Gill

Risultato della ricerca: Articlepeer review

39 Citazioni (Scopus)

Abstract

Loss of the tumor suppressor gene AT-rich interactive domain-containing protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic role is unknown. We aimed to investigate the risk associated with loss of ARID1A (ARID1A-) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS search from database inception until 01/31/2015 without language restriction was conducted, contacting authors for unpublished data. Eligible were prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of ARID1A (ARID1A+) vs. ARID1A-, assessed either via immunohistochemistry (loss of expression) or with genetic testing (presence of mutation). Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time-dependent risk related to ARID1A- adjusted for potential confounders. Of 136 hits, 25 studies with 5,651 participants (28 cohorts; ARID1A-: n = 1,701; ARID1A+: n = 3,950), with a mean follow-up period of 4.7 ± 1.8 years, were meta-analyzed. Compared to ARID1A+, ARID1A- significantly increased cancer-specific mortality (studies = 3; RR = 1.55, 95% confidence interval (CI) = 1.19-2.00, I2 = 31%). Using HRs adjusted for potential confounders, ARID1A- was associated with a greater risk of cancer-specific mortality (studies = 2; HR = 2.55, 95%CI = 1.19-5.45, I2 = 19%) and cancer recurrence (studies = 10; HR = 1.93, 95%CI = 1.22-3.05, I2 = 76%). On the basis of these results, we have demonstrated that loss of ARID1A shortened time to cancer-specific mortality, and to recurrence of cancer when adjusting for potential confounders. For its role, this gene should be considered as an important potential target for personalized medicine in cancer treatment.
Lingua originaleEnglish
pagine (da-a)39088-39097
Numero di pagine10
RivistaOncotarget
Volume6
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo